Sotera Health Co 8K

Sotera Health Company announced strong Q2 and first-half 2026 results, reduced leverage and interest costs, completed its final sponsor secondary offering, and raised its full-year 2026 financial outlook.

On August 6, 2026, Sotera Health Company reported strong financial results for the second quarter and first half of 2026, including Q2 net revenues growth of 9.2% year over year (8.0% on a constant currency basis), a sharp increase in net income to $54 million ($0.19 per diluted share) from $8 million ($0.03 per diluted share) in Q2 2025, and a 10.0% rise in Adjusted EBITDA with margin expansion to 51.6%, driven by solid performance across its Sterigenics, Nordion, and Nelson Labs segments, while also achieving a net leverage ratio of 3.0x, repricing its term loan to reduce annual interest expense by approximately $3.5 million, completing the final private equity sponsor secondary offering, and raising its full‑year 2026 outlook for net revenues, Adjusted EBITDA, interest expense, tax rate, and Adjusted EPS.

Filing Facts

CIK

1822479

Ticker

-

Form

8K

Source Type

sec

Accession

0001822479-26-000044

Alert Tier

7